GlobeNewswire

Nexstim to Present in Three Investor Events in November and December

Share

Press Release, Helsinki, 23 November 2020 at 11.00 am (EET)

Nexstim to Present in Three Investor Events in November and December

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that the company’s CEO Mikko Karvinen will be presenting in three different investor events in late November and early December.

The presentations will provide an overview of the company including both the therapeutic and diagnostic business as well as an update on the recent news.

All the events are organised online. The events and Nexstim’s presentation times are:

      ·Redeye Life Science Day on Thursday 26 November 2020 at 12.10 (CET)
Read more >>>

      ·ProHearings Shared Capital Markets Day on Friday 27 November 2020 at 10.40 (CET)
Read more >>>

      ·Redeye Investor Forum on Thursday 3 December 2020 at 15.40 (CET)
Read more >>>

Nexstim’s presentations will be available for everyone as video recordings after the events.

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

German University Hospital Orders Nexstim NBS System with NexSpeech28.1.2021 10:40:00 CETPress release

Press release, Helsinki, 28 January 2021 at 11.40 am (EET) German University Hospital Orders Nexstim NBS System with NexSpeech Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that a University Hospital in Germany has ordered a Nexstim NBS System with NexSpeech. The hospital is a new customer for Nexstim. The NBS System with NexSpeech will be used for neuroscientific research and diagnostics. Nexstim NBS System uses the unique SmartFocus® navigated transcranial magnetic stimulation (nTMS) technology which enables accurate and precise stimulation of the brain. SmartFocus® nTMS mapping conducted with NBS system is a non-invasive and accessible way of diagnosing the tumour’s or other lesion’s location. In addition to motor mapping, NBS System can be used also for locating language eloquent areas when used together with NexSpeech module. Mikko Karvinen, CEO of Nexstim, said: “I’m very happy to welcome this new hospital and its team to our SmartFocus® nTMS user communit

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS28.1.2021 10:10:00 CETPress release

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-01-28Loan195Coupon1.00 %ISIN-codeSE0013546066Maturity2025-06-18 Tendered volume, SEK mln1,300 +/- 650 Volume offered, SEK mln4,250Volume bought, SEK mln1,300Number of bids9Number of accepted bids5Average yield0.040 %Lowest accepted yield0.038 %Highest yield0.044 %% accepted at lowest yield 57.14 Auction date2021-01-28Loan1590Coupon1.00 %ISIN-codeSE0012676690Maturity2025-09-03 Tendered volume, SEK mln1,500 +/- 750 Volume offered, SEK mln5,926Volume bought, SEK mln1,500Number of bids12Number of accepted bids3Average yield0.066 %Lowest accepted yield0.061 %Highest yield0.068 %% accepted at lowest yield 29.87 Auction date2021-01-28Loan146Coupon0.50 %ISIN-codeSE0013381571Maturity2025-06-11 Tendered volume, SEK mln800 +/- 400 Volume offered, SEK mln4,500Volume bought, SEK mln800Number of bids12Number of accepted bids1Average yield0.073 %Lowest accepted yield0.073 %Highest yield0.073 %% accepted at lowest yield 100.00 Auc

Share Buyback Transaction Details January 21 – 27, 202128.1.2021 10:00:00 CETPress release

Share Buyback Transaction Details January 21 – 27, 2021 January 28, 2021 - Wolters Kluwer today reports that it has repurchased 99,498 of its own ordinary shares in the period from January 21, 2021, up to and including January 27, 2021, for €6.9 million and at an average share price of €69.79. These repurchases are part of the share buyback program announced on October 30, 2020, under which we intend to repurchase shares for up to €50 million during the period starting January 4, 2021, up to and including February 22, 2021. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2021 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€)2021 to date 357,57525.069.91 For the above-mentioned period, we have engaged a third party to execute €50 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Associati

Rockridge Intersects 2.5 g/t Au over 13.0m containing 9.6 g/t Au over 2.0m and Makes New Gold Discovery 250m West of Main Zone; Assays Pending for Two Additional Holes28.1.2021 09:30:00 CETPress release

VANCOUVER, British Columbia, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Rockridge Resources Ltd.(TSX-V: ROCK)(OTCQB: RRRLF) (Frankfurt: RR0) (“Rockridge”) (the “Company”) is pleased to announce that it has completed a 2,965 metre diamond drilling program at its 100% owned Raney Gold Project located southwest of Timmins, Ontario, Canada (the “Raney Gold Project” or “Property”). A total of 11 drill holes were completed to evaluate the down plunge and strike extent of the Raney Gold Zone. Assays have been received for 9 of the 11 holes with gold mineralization intersected in all but two holes. Drill hole RN 20-13 returned 2.5 g/t Au over 13.0m from 133.0m to 146.0m including 3.41 g/t Au over 9.0m from 135.0m to 144.0m and including 9.6 g/t Au over 2.0m from 135.0m to 137.0m. Furthermore, exploratory drill hole RN 20-18 was a significant step out hole along strike 250m to the west of the main zone and returned 1.36 g/t Au over 9.0m from 141.0m to 150.0m including 2.1 g/t Au over 4.0m from 141.0m to

Vital Partners with Radboud University Medical Center to Deliver Next Generation VNA, a Data Orchestration Engine28.1.2021 09:00:00 CETPress release

MINNETONKA, Minn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Vital, a Canon Group company, has been awarded a contract by Radboud University Medical Center of Nijmegen, Netherlands. This announcement was preceded by an extensive, production-ready proof of concept, in which Vital proved to be a reliable partner as it successfully integrated its Vendor Neutral Archive (VNA) solution with Radboud's existing architecture and workflow. With Vital's VNA connecting Radboud's data silos, Radboud was able to promote efficiency at all levels of care. Radboud now has the ability to free key information from proprietary software, having data readily available at faster rates. This helps support Radboud's goal of ensuring every patient always receives the best care, now and in the future. “We needed a scalable vendor-agnostic solution that could consistently connect data within our systems.” says Laurens de Grootwe, a Lead Product Owner in Information Management at Radboud UMC. “We found that solution with

Stolt-Nielsen Limited Reports Unaudited Results For the Fourth Quarter and Full Year 202028.1.2021 08:30:00 CETPress release

LONDON, January 28, 2021 – Stolt-Nielsen Limited (Oslo Børs: SNI) today reported unaudited results for the fourth quarter ended November 30, 2020. The Company reported a fourth-quarter net profit attributable to shareholders of $13.4 million, with revenue of $480.6 million, compared with a net profit attributable to shareholders of $29.2 million, with revenue of $474.0 million, in the third quarter of 2020. The net profit attributable to shareholders for the full year was $26.3 million, with revenue of $1,955.1 million, compared with a net profit attributable to shareholders of $21.0 million, with revenue of $2,032.1 million, in 2019. Highlights for the fourth quarter, compared with the third quarter of 2020, were: Stolt Tankers reported improved operating profit of $31.9 million, up from $28.1 million, as the negative impact of lower volumes was more than offset by a reduction in shipowning costs.The Stolt Tankers Joint Service Sailed-in Time-Charter Index was 0.60, compared with 0.61

Cargotec closed the syndication of the merger financing arrangement28.1.2021 08:00:00 CETPress release

CARGOTEC CORPORATION, PRESS RELEASE, 28 JANUARY 2021 AT 9:00 AM Cargotec closed the syndication of the merger financing arrangement Cargotec has closed the syndication regarding an EUR 300 million Term Loan Facility. The syndication was launched on the 30th November 2020 and the commitments received from the banks in the syndication led to significant oversubscription. Nordea Bank Abp managed the syndication process as Mandated Lead Arranger, Bookrunner and Exclusive Underwriter of the Facility. BNP Paribas, Danske Bank, OP Corporate Bank plc and SEB joined the facility as Mandated Lead Arrangers. Citi, Commerzbank Aktiengesellschaft, Crédit Agricole Corporate and Investment Bank, DBS Bank Ltd., London Branch, Deutsche Bank AG, Handelsbanken, Helaba, ING Belgium S.A./N.V., Santander, Standard Chartered and Swedbank AB (publ) were acting as Lead Arrangers. For further information, please contact: Mikko Puolakka, Executive Vice President and CFO, tel. +358 20 777 4105 Hanna-Maria Heikkin